title: Drug-induced eosinophilia and systemic symptoms: hypersensitivity or peripheral T-cell lymphoma?
authors.forename: Nicolas
authors.initials: N
authors.lastname: Schleinitz
authors.forename: Véronique
authors.initials: V
authors.lastname: Veit
authors.forename: Diane
authors.initials: D
authors.lastname: Coso
authors.forename: Thérèse
authors.initials: T
authors.lastname: Aurran
authors.forename: Phillippe
authors.initials: P
authors.lastname: Berbis
authors.forename: Jean-Robert
authors.initials: JR
authors.lastname: Harle
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001707:Biopsy, Needle; D003520:Cyclophosphamide / Q000627:therapeutic use; D003937:Diagnosis, Differential; D004008:Diclofenac / Q000009:adverse effects* / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D004342:Drug Hypersensitivity / Q000175:diagnosis*; D004890:Erythema / Q000139:chemically induced / Q000473:pathology*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007150:Immunohistochemistry; D017116:Low Back Pain / Q000175:diagnosis / Q000188:drug therapy*; D016411:Lymphoma, T-Cell, Peripheral / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology*; D011239:Prednisolone / Q000627:therapeutic use; D018570:Risk Assessment; D016896:Treatment Outcome; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D004008:Diclofenac; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone